Ticar

ANDA 62690, held by Glaxosmithkline. Ticarcillin Disodium.

As of Nov 15, 2026, ANDA 62690 (Ticar), held by Glaxosmithkline, was first approved by FDA on Dec 19, 1986, with 4 approved supplements and 0 published complete response letters.

First approved: Dec 19, 1986
Supplements approved: 4
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 5 submissions below

Date	Submission	Status	Documents
Dec 19, 1986	Original application	Approved	None posted

Products

1 strengths and forms

Product	Active ingredient	Marketing
TicarEQ 3GM BASE/VIAL · injectable;injection	Ticarcillin Disodium	Discontinued

All 5 submissions, including labeling and manufacturing supplements


Jul 3, 1996	Supplement 5Manufacturing	Approved	None posted
Jul 3, 1996	Supplement 6Manufacturing	Approved	None posted
Feb 26, 1993	Supplement 3Labeling	Approved	None posted
Feb 26, 1990	Supplement 2Manufacturing	Approved	None posted
Dec 19, 1986	Original application	Approved	None posted

Identifiers

Application: ANDA 62690
Drugs@FDA: Overview at FDA
Company: GlaxoSmithKline LLC

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters